November 20, 2021
Read for 2 minutes
Source / information
Source:
DeBiasi, R. Multisystem Inflammatory Syndrome in Children. Presented at: Symposium on Infectious Diseases in Children; 20.-21. November 2021; New York (hybrid meeting).
Disclosure:
DeBiasi does not report any relevant financial information.
ADD SUBJECT TO EMAIL ALERTS
Receive an email when new articles are published on
Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If this problem persists, please contact [email protected].
Back to Healio
NEW YORK – Rises in multisystem inflammatory syndrome in children or MIS-C are “almost predictable” according to an expert presentation.
Roberta DeBiasi, MD, MS, director of pediatric infectious diseases at Children’s National Medical Center in Washington, DC, made the presentation on the first day of the 34th annual symposium on infectious diseases in children.
An expert said in a presentation at the Infectious Diseases in Children Symposium that MIS-C surges were “almost predictable” after waves of COVID-19. Source: Adobe Stock
“We’ve had three climbs now,” said DeBiasi, “and they always come about 4 to 6 weeks after we’ve seen the peak of our COVID-19.”
DeBiasi also reported that although COVID-19 cases at her hospital were decreasing, MIS-C cases were “trending up”.
“But what we try, we and many other centers [are] try to find a signature – not just for MIS-C, but for certain types of MIS-C – so that you can tailor the best therapy for each MIS-C type, ”she continued.
She added that a study of cytokines in the blood during the first wave of MIS-C gave her colleagues a crucial answer.
“Most of all, we wanted to know if there was something about the virus that made it more likely to get MIS-C compared to primary COVID?” Said DeBiasi. “And the answer was no, it was an equivalent representation of the virus versions in circulation at the time. So at our center we’ve worked really hard to have a cohort that can be tracked over time and treated equally over time because that really adds to the data. “
The CDC’s case definition for MIS-C is any patient under the age of 21 who has been tested with fever, laboratory evidence of inflammation, evidence of a clinically serious illness requiring hospitalization, with two or more organs involved, who has no alternative plausible diagnosis , presents positive for a current or recent SARS-CoV-2 infection, or reports exposure to a suspected or confirmed case of COVID-19.
DeBiasi said that post-MIS-C long COVID is something she is collaborating with the NIH on a long-term study of which she is the lead researcher.
“We are working with the NIH to enroll large numbers of children because we have large numbers in our center,” DeBiasi said. “Our goal is to have 1,000 children who have either COVID-19 or MIS-C and then compare them to 1,000 healthy contacts either in their home or college or wherever they have been. We will follow these children for 3 years to see the effects and we hope to learn a lot over the next few years. “
ADD SUBJECT TO EMAIL ALERTS
Receive an email when new articles are published on
Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If this problem persists, please contact [email protected].
Back to Healio
